Charlotte’s Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products

LOUISVILLE, Colo., March 20, 2026 /PRNewswire/ – (TSX: CWEB) (OTCQB: CWBHF) Charlotte’s Web Holdings, Inc. (the „Company“ or „Charlotte’s Web„), a botanical wellness innovation company and the market leader in cannabidiol („CBD„) hemp extract wellness products, extends its sincere appreciation to the Centers for Medicare & Medicaid Services (CMS) and the Administration for their leadership in advancing structured access to eligible full‑spectrum hemp products through current CMS Innovation Center models, as reflected in CMS’s new Substance Access Beneficiary Engagement Incentive (BEI) guidance pages. Under the BEI, CMS has defined eligible hemp products to include orally administered products containing up to 3 mg per serving of tetrahydrocannabinols, a threshold that accommodates non-intoxicating full-spectrum hemp-derived CBD products. This forward‑looking framework supports patient‑provider discussions around eligible hemp products, reinforcing science‑driven policymaking that prioritizes consumer safety and product quality.

„We are grateful for CMS’s thoughtful approach in expanding access and creating space for responsible, evidence‑based hemp wellness conversations in clinical settings,“ said Bill Morachnick, CEO of Charlotte’s Web. „This program aligns with our mission to advance safe, high‑quality, science‑backed hemp options for consumers, and we remain committed to supporting sensible legislation that protects patients and strengthens the integrity of our industry.“